Dianthus Therapeutics (DNTH) Cash & Equivalents (2017 - 2025)
Dianthus Therapeutics (DNTH) posted quarterly Cash & Equivalents of $51.1 million for Q4 2025, up 124.14% year-over-year from $22.8 million in Q4 2024, and down 8.75% quarter-over-quarter from $56.0 million in Q3 2025.
Dianthus Therapeutics (DNTH) Cash & Equivalents (2017 - 2025) Analysis & Trends
Dianthus Therapeutics' Cash & Equivalents history runs 9 years deep, the most recent figure standing at $51.1 million for Q4 2025.
- In Q4 2025, Cash & Equivalents rose 124.14% year-over-year to $51.1 million; the TTM figure through Dec 2025 stood at $51.1 million (up 124.14% YoY), while the FY2025 annual figure was $51.1 million, up 124.14% from the prior year.
- Cash & Equivalents for Q4 2025 stood at $51.1 million, down from $56.0 million in the prior quarter.
- The five-year high for Cash & Equivalents was $329.7 million in Q1 2024, with the low at $10.1 million in Q1 2025.
- The 5-year median for Cash & Equivalents is $53.0 million (2022), against an average of $92.8 million.
- The sharpest annual moves came in 2024 and 2025: Cash & Equivalents jumped 1320.49% in 2024, then slumped 96.93% in 2025.
- Dianthus Therapeutics' Cash & Equivalents stood at $131.6 million in 2021, then slumped by 88.33% to $15.4 million in 2022, then surged by 761.21% to $132.3 million in 2023, then sank by 82.78% to $22.8 million in 2024, then soared by 124.14% to $51.1 million in 2025.
- Business Quant data shows DNTH's Cash & Equivalents at $51.1 million in Q4 2025, $56.0 million in Q3 2025, and $13.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Dianthus Therapeutics | 4.97 Bn | 4.57 Bn | - | 51.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 51.09 Mn |
| Sep 30, 2025 | 55.98 Mn |
| Jun 30, 2025 | 13.24 Mn |
| Mar 31, 2025 | 10.12 Mn |
| Dec 31, 2024 | 22.79 Mn |
| Sep 30, 2024 | 33.67 Mn |
| Jun 30, 2024 | 314.17 Mn |
| Mar 31, 2024 | 329.72 Mn |
| Dec 31, 2023 | 132.33 Mn |
| Sep 30, 2023 | 157.28 Mn |
| Jun 30, 2023 | 40.28 Mn |
| Mar 31, 2023 | 23.21 Mn |
| Dec 31, 2022 | 15.37 Mn |
| Sep 30, 2022 | 36.88 Mn |
| Jun 30, 2022 | 54.83 Mn |
| Mar 31, 2022 | 71.77 Mn |
| Dec 31, 2021 | 131.65 Mn |
| Sep 30, 2021 | 157.54 Mn |
| Jun 30, 2021 | 155.03 Mn |
| Mar 31, 2021 | 49.29 Mn |